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Background
Cellca is a recognized leader in cell line and upstream
process development for large-scale protein production
of biopharmaceuticals (e.g. antibodies) in mammalian
cells and offers a unique platform technology which is
characterized by high efficiency regarding productivity,
scalability, and protein quality. As the market for thera-
peutic proteins is steadily growing, the need to optimize
methods for the generation of mammalian cell lines is
steadily increasing. In this context, important aspects
are to express recombinant proteins not only at high
levels and in an efficient cost-effective manner, but also
with the desired protein quality attributes such as the
glycoprofile. Cellca’s unique platform technology enables
the expression of antibody products with different pro-
tein quality attributes using only a single host cell line.
We identified three steps to select, optimize and con-
firm scalability of a high-producing cell line expressing
proteins with the desired quality profile. Thus, with this
study we aim to contribute to a better understanding of
how quality in terms of expressing proteins with pre-
defined glycoprofiles can be built into a cell line and
process development process.
Materials and methods
A recombinant CHO DG44 cell line expressing an IgG1
antibody was developed using Cellca´s proprietary plat-
form technology. For this purpose, different cell clones
were generated and subsequently evaluated in a platform
fed-batch process at shake flask scale for their producer
cell line potential. Product quality analysis was imple-
mented into the development process early on and
allowed selection of the clone with the most desirable
product quality profile. For media and process variation
studies, cells were cultured in fed-batch mode in both
shake flask and bioreactor scale using Cellca’s platform
process and proprietary cell culture media. Cell densities
and culture viabilities were obtained using a CASY cell
counter. Antibody concentrations were determined by
Protein A HPLC. Bioreactor experiments in 200 L and
1000 L scale were performed at Rentschler Biotechnolo-
gie GmbH (Laupheim, Germany). Analytical data of pro-
duct quality was provided by Protagen Protein Services
GmbH (Dortmund, Germany). The Galactosylation
index was calculated according to Kunkel et al [1].
Results
The basis for all development work herein described was
the Cellca CHO DG44 host cell line which offers a broad
flexibility expressing different antibody products regard-
ing several quality attributes. We identified three steps to
select, optimize and confirm the scalability of a high-
producing cell line expressing proteins with the desired
quality profile. In the first step, suitable cell clones
needed to be selected: In a quality by design approach it
is crucial to have a sufficient amount of high producing
cell clones available. Based on the fed-batch performance
in a standard process, 48 high producing clones were
analyzed for the desired target protein quality profile (see
exemplary results in Figure 1A). The selection of the
clones with the most promising quality profile was facili-
tated by the knowledge of media and process optimiza-
tion capabilities. The protein quality profile of an
antibody can be actively influenced by fed-batch process
and culture media design. Thus, in the second step, sev-
eral conditions, like media components, process para-
meters or feeding regimen, were tested and conditions to* Correspondence: c.noack@cellca.de
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increase or reduce galactosylation profiles could be iden-
tified. They have been successfully applied for different
antibody products at Cellca. Selection of the optimal pro-
cess and media conditions can therefore help to obtain
the desired protein quality (Figure 1B). In the third step,
the scalability of the fed-batch process optimized in 25
mL shake flask was studied. As shake flask processes at
Cellca are designed to serve as bioreactor scale-down
model, the scale-up to different bioreactors up to 1000 L
volume could be easily performed without further opti-
mization or extensive adjustments. During scale-up, not
only productivity and cell growth were comparable to the
shake flask model, but also protein quality attributes of
the produced antibody (Figure 1C). This proven scalabil-
ity is a key factor for optimization in small scales.
Conclusions
It becomes increasingly important to express recombi-
nant proteins not only at high levels and in an efficient
cost-effective manner, but also with the desired protein
quality attributes, e.g. the glycoprofile. In this study, we
presented an approach of how quality in terms of
expressing proteins with pre-defined glycoprofiles can
be built into a cell line and process development
process.
A main building block and starting point for cell line
development is Cellca’s CHO DG44 host cell line, which
can be flexibly used to produce antibodies that cover a
broad range of various quality attributes. Thus, there is
no need to screen several host cell lines for expression
of the correct target antibody characteristics, as one cell
line and the technology platform associated with it is
sufficient to express different antibody products each
with their individual protein quality attributes. In the
present study, we developed a recombinant cell line
expressing a monoclonal human IgG1 antibody. Imple-
menting a quality by design approach for pool and
clone selection allowed to pre-select cell pools based on
their glycan profile before single cell cloning. Subse-
quently, high-producing cell clones that expressed the
target antibody with a desirable protein quality profile
were identified in a standard fed-batch process and used
for further studies. We showed that the galactosylation
profile can be influenced, both towards higher and
lower galactosylation levels, by media and process varia-
tion. As depicted in Figure 1B, effective clone selection
as well as media and process optimization enabled to
match the N-glycosylation pattern of the expressed IgG1
antibody to a reference protein. The optimized produc-
tion process was scalable from 25 mL shake flask up to
1000 L bioreactor levels regarding growth, productivity
Figure 1 A) Six clones derived from cell pool LPB were
analyzed for fed-batch performance and protein quality
attributes of the model IgG1 antibody. B) Effective clone
selection as well as media and process optimization enables to
match the N-glycosylation pattern of a reference protein. C)
Scalability of the fed-batch process from shake flask to bioreactor
scale has been demonstrated for different clones and is exemplarily
shown for an IgG1 antibody.
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and glycosylation. Implementing the quality by design
approach into cell line and process development
can thus enable to successfully target a desired protein
quality profile.
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